TrialScientific reports2016

Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer.

Doris Posch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.